Vascular Ehlers-Danlos Syndrome
8
3
4
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
25%
2 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (8)
Metabolic Phenotyping in vEDS
Pathogenetic Basis of Aortopathy and Aortic Valve Disease
Clinical Trial to Compare the Efficacy of Celiprolol to Placebo in Patients With Vascular Ehlers-Danlos Syndrome
Single-Session "Empowered Relief" Class for Marfan Syndrome and Related Conditions
Heart Coherence Training on Vascular Ehlers-Danlos Syndrome Patients
Investigate Efficacy, Safety, and Pharmacokinetics of Enzastaurin for the Prevention of Arterial Events in Patients With Vascular Ehlers-Danlos Syndrome.
Characterization of Bleeding Disorders in EDS
Biomarkers in Vascular Ehlers-Danlos Syndrome